Business Description
Ectin Research AB
ISIN : SE0015987714
Compare
Compare
Traded in other countries / regions
ECTIN B.Sweden IPO Date
2021-08-18Description
Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.16 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.4 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -215.9 | |||||
| 3-Year EPS without NRI Growth Rate | -145.6 | |||||
| 3-Year Book Growth Rate | -26.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.47 | |||||
| 9-Day RSI | 41.09 | |||||
| 14-Day RSI | 40.63 | |||||
| 6-1 Month Momentum % | -75.79 | |||||
| 12-1 Month Momentum % | -74.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.47 | |||||
| Quick Ratio | 2.47 | |||||
| Cash Ratio | 2.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -1.09 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -146.58 | |||||
| ROA % | -123.28 | |||||
| ROIC % | -129.81 | |||||
| ROC (Joel Greenblatt) % | -150758.93 | |||||
| ROCE % | -137.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.36 | |||||
| Price-to-Tangible-Book | 0.36 | |||||
| EV-to-EBIT | 0.15 | |||||
| EV-to-EBITDA | 0.15 | |||||
| EV-to-FCF | 0.32 | |||||
| Price-to-Net-Current-Asset-Value | 0.36 | |||||
| Price-to-Net-Cash | 0.49 | |||||
| Earnings Yield (Greenblatt) % | 666.67 | |||||
| FCF Yield % | -1143.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ectin Research AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -1.34 | ||
| Beta | 0 | ||
| Volatility % | 235.46 | ||
| 14-Day RSI | 40.63 | ||
| 14-Day ATR (kr) | 0.065188 | ||
| 20-Day SMA (kr) | 0.0822 | ||
| 12-1 Month Momentum % | -74.32 | ||
| 52-Week Range (kr) | 0.0005 - 1.48 | ||
| Shares Outstanding (Mil) | 12.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ectin Research AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ectin Research AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ectin Research AB Frequently Asked Questions
What is Ectin Research AB(XSAT:ECTIN B)'s stock price today?
The current price of XSAT:ECTIN B is kr0.05. The 52 week high of XSAT:ECTIN B is kr1.48 and 52 week low is kr0.00.
When is next earnings date of Ectin Research AB(XSAT:ECTIN B)?
The next earnings date of Ectin Research AB(XSAT:ECTIN B) is 2025-02-20 Est..
Does Ectin Research AB(XSAT:ECTIN B) pay dividends? If so, how much?
Ectin Research AB(XSAT:ECTIN B) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers